drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous, gene-modified CAR T-cell therapy; patient T cells engineered to express a chimeric antigen receptor targeting CD19 to induce targeted cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an anti‑CD19 chimeric antigen receptor. Binding to CD19 on B‑lineage cells triggers MHC‑independent T‑cell activation (CD3ζ with costimulation), resulting in proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of CD19+ malignant B cells, with on‑target depletion of CD19+ cells.
drug_name
CAR19
nct_id_drug_ref
NCT06911710